Human Papillomavirus and Extragenital in situ Carcinoma

Quéreux, G.; Nguyen, James; Dréno, Brigitte

doi:10.1159/000078585

Cited by 25 publications

(17 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This condition is also histologically characterized by in situ SCC lesions but, in contrast to BD, bowenoid papulosis lacks full‐thickness epidermal atypia. PV DNA is uncovered in virtually all samples of bowenoid papulosis but data concerning the presence of PV in human BD remain contradictory 22–25 . Furthermore, PVs that infect human bowenoid papulosis and BD are usually to mucosal and not to cutaneous strains 23,24 .…”

Section: Discussionmentioning

confidence: 99%

Clinical, histological and immunohistochemical study of feline viral plaques and bowenoid in situ carcinomas

Wilhelm

Degorce‐Rubiales²,

Godson

et al. 2006

Veterinary Dermatology

View full text Add to dashboard Cite

Feline viral plaques (FVP) induced by papillomavirus (PV) are often hyperpigmented and flat warts. The fact that up to 47% of bowenoid in situ carcinomas (BISC), which also usually occur in the form of hyperpigmented plaques, are positive for PV antigen in immunochemistry suggests that BISC could evolve from FVP. The relationship between the presence of PV antigens and the clinical and histological features of 26 cases of feline dermatoses (clinically described as pigmented plaques and with histological diagnosis of FVP and/or BISC) was therefore determined. The cases were classified into one of the three following groups: FVP, FVP + BISC or BISC. Immunohistological detection of papillomavirus group-specific antigen was performed using a polyclonal rabbit antibovine papillomavirus antiserum. Of the seven cases in the FVP group, six were deemed positive by immunohistology as were all 10 cats in the FVP + BISC group. On the other hand, only one of the nine BISC cats was positive. The presence of both FVP and BISC lesions in some cats and the high detection rate of PV antigens in the FVP and FVP + BISC groups suggest that both conditions might have the same viral cause and that some BISC may evolve from FVP. The low rate of viral antigen detection in the BISC group indicates another cause or a loss of viral replication during the cancerogenesis.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical, histological and immunohistochemical study of feline viral plaques and bowenoid in situ carcinomas

Wilhelm

Degorce‐Rubiales²,

Godson

et al. 2006

Veterinary Dermatology

View full text Add to dashboard Cite

show abstract

“…25 HPV DNA has been demonstrated in extragenital SCC in situ in varying amounts from 4Á8-60%. 24,[26][27][28] It appears that HPV16 may be particularly relevant with regard to development of SCC in situ on the hands and feet; it has been implicated in 60% of palmoplantar and periungual lesions 29 ; and (v) others: chronic injury or dermatoses (such as lupus vulgaris or chronic lupus erythematosus) have been implicated. 30 …”

Section: Aetiologymentioning

confidence: 99%

BritishAssociation ofDermatologists' guidelines for the management of squamous cell carcinomain situ(Bowen's disease) 2014

et al. 2014

View full text Add to dashboard Cite

“…A viral aetiology has been implicated in humans and suggested in felids. Papillomavirus has been detected in lesions of Bowen’s disease in humans 3–7 and near MSCCIS lesions in cats 8…”

Section: Introductionmentioning

confidence: 99%

Use of imiquimod 5% cream (Aldara™) in cats with multicentric squamous cell carcinoma in situ: 12 cases (2002–2005)*

Gill

Bergman

Baer

et al. 2008

Vet Comparative Oncology

View full text Add to dashboard Cite

Multicentric squamous cell carcinoma in situ (MSCCIS) is a variant of squamous cell carcinoma in cats, commonly referred to as Bowen's-like disease. Imiquimod 5% cream (Aldara) is a novel immune response modifier (IRM) that has been reported as a successful treatment for Bowen's disease in humans. The purpose of this study was to describe clinical findings, treatment protocols and survival in cats with MSCCIS treated with imiquimod 5% cream and to examine the effects of imiquimod 5% cream in cats with MSCCIS. The expression of papillomavirus group-specific antigen in the study population was also determined. From review of medical records, 12 cats were identified with a histologic diagnosis of MSCCIS and treatment with imiquimod 5% cream. Initial lesions responded to imiquimod 5% cream in all cats. Most cats (75%) developed new lesions. New lesions also responded to imiquimod 5% cream in all cats treated. Five cats (41%) had side effects suspected to be associated with the use of imiquimod 5% cream, including local erythema (25%), increased liver enzymes and neutropenia (8%), and partial anorexia and vomiting (8%). Kaplan-Meier median treatment duration and median survival time probabilities for cats in this study were 1189 days, respectively. A time to failure model was generated as many cats were censored from analysis well before the aforementioned projected median. This model resulted in a shorter median survival time of 243 days. No patient-related, tumour-related or treatment-related prognostic variables were identified. No expression for papilloma group-specific antigen was found. Imiquimod 5% cream appears to be well tolerated in the majority of cats, and further studies are warranted to further examine its usefulness in cats with this disease.

show abstract

Human Papillomavirus and Extragenital in situ Carcinoma

Cited by 25 publications

References 36 publications

Clinical, histological and immunohistochemical study of feline viral plaques and bowenoid in situ carcinomas

Clinical, histological and immunohistochemical study of feline viral plaques and bowenoid in situ carcinomas

BritishAssociation ofDermatologists' guidelines for the management of squamous cell carcinomain situ(Bowen's disease) 2014

Use of imiquimod 5% cream (Aldara™) in cats with multicentric squamous cell carcinoma in situ: 12 cases (2002–2005)*

Contact Info

Product

Resources

About